Extensive Research and Increasing Demand for Oligonucleotide Synthesis, Drives The Oligonucleotide Synthesis Market

Pune, India, January, 2022/MRFR Press Release/- Market Research Future Published a Half Cooked Research Report on “Global  Oligonucleotide Synthesis Market Research Report - Forecast to 2030”– Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2030.

 Global Oligonucleotide Synthesis Market   - Overview

The Oligonucleotide Synthesis Market is expected to reach USD 27.2619 billion by 2030 at 16.50 % CAGR during the forecast period 2023-2030.

Oligonucleotide synthesis is a process for the synthesis of short fragments of nucleic acids with defined chemical structure. It is required for various life sciences applications which include research, diagnostics & therapeutics and various others. These applications are majorly based on two types of oligonucleotide pool that are DNA pool and RNA pool.

Oligonucleotide synthesis market is driven by three major factors such as huge investments from big pharmaceutical companies in oligonucleotide therapeutics for drug development, CMO’s involvement in manufacturing therapeutic oligonucleotides and wide application areas offered by the oligonucleotides. Additionally, increasing prevalence of chronic diseases, thus increasing the demand for diagnosis and treatment, fuel the growth of the market.

Companies to Watch

Integrated DNA Technologies, Inc (U.S), GE Healthcare (U.S.), Agilent Technologies Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Bioautomation Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), L.G.C Biosearch Technologies (U.S.), Eurofins Genomics (Germany), Eurogentec S.A (Belgium), and Nitto Denko Avecia Inc. (Japan) and others. are some of the prominent players at the forefront of competition in the global Oligonucleotide Synthesis market and are profiled in MRFR Analysis.

Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.

Developments

Integrated DNA Technologies, Inc:

February, 2017 - Integrated DNA Technologies, Inc. had announced the acquisition of oligo manufacturing business of GeneWorks (Australia). This acquisition by the company enhances the capacity for direct sales of genomic products in Asia-Pacific region.  Integrated DNA Technologies, Inc (IDT) is one of the leading biotechnology company that is involved in manufacturing, developing nucleic acid products for the life sciences industry. The company mainly sells and distributes short strands of DNA called oligonucleotides. The company’s essential business is the creation of custom oligonucleotides for molecular biology applications. IDT has created restrictive innovations for genomics applications, which include generation sequencing, CRISPR genome editing, qPCR, and RNA interference. The products offered by the company serves many of the small university academic research, biotechnology, clinical diagnostics, and pharmaceutical development all around the world. The company is specialized in Custom Oligonucleotides, DNA Synthesis, Synthetic Biology, RNA Synthesis, Synthesis Reagents, Next generation sequencing, Nucleic Acid Synthesis, Genes & gene fragments, Primers, GMP Manufacturing, Genotyping, Probes, RNAi, qPCR, and CRISPR genome editing.

Agilent Technologies Inc.:

January 2017: Agilent Technologies Inc.announced its collaboration with the Centre for Human Genetics of the University of Leuven and the University Hospital of Leuven in Belgium.

December, 2016: Agilent Technologies Inc. announced the acquisition of Multiplicom N.V., a Leading European Diagnostics Company. On this acquisition Herman Verrelst, vice president said “The acquisition of Multiplicom significantly strengthens our presence in the genomics market". Agilent is one of the leaders in life sciences, diagnostics and applied chemical markets. The company provides services to laboratories all around the world with its instruments, services, consumables, applications and expertise. Agilent mainly focuses on six major industries which involve food, environmental and forensics, pharmaceutical, diagnostics, chemical and energy and research. The company with its three brands CrossLab combines, Dako Agilent Pathology Solutions and Agilent OpenLAB Software Suite is innovating and providing special services to laboratories with high technology.

December 2016: The Scientist magazine named two of company’s CRISPR-Cas9 genome editing tools among the Top 10 Innovations of 2016. The Invitrogen LentiArray CRISPR libraries was ranked 5th; and the GeneArt Platinum Cas9 Nuclease earned the 10th spot.

Bioautomation Corporation:

BioAutomation an American company in 2012 announced the agreement with Alliance Global under which Alliance Global will present BioAutomation's full scope of DNA/RNA oligonucleotide synthesizers to more than 50 markets over the Middle East and African region.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Oligonucleotide Synthesis Market Research Report

Regional Analysis

The major factor that influences the growth of the North American oligonucleotide synthesis market is the existence of large number of small scale and big scale manufacturers of oligonucleotides and service providers in the region.

According to survey of National Centre for Chronic Disease Prevention and Health Promotion (CDC) in United States every year 7 out of 10 individuals die due to chronic diseases and 86% of healthcare costs in the country. With oligonucleotide playing a major role in treatment of chronic diseases market for oligonucleotide synthesis is expected to grow gradually in the forecasted period.